View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 20, 2021

Enzychem’s EC-18 reduces occurrence of oral mucositis in Phase II trial

The therapy met the primary and secondary endpoints in the trial in chemoradiation-induced oral mucositis patients.

Enzychem Lifesciences has reported that its lead candidate, EC-18, decreased the duration and occurrence of severe oral mucositis in a Phase II clinical trial in head and neck cancer patients.

A new small molecule oral immunomodulator, EC-18 is being analysed for chemoradiation-induced oral mucositis (CRIOM). It potentially aids in resolving inflammation and quick return to homeostasis.

Carried out in the US, the Phase II trial assessed EC-18 to treat oral mucositis in individuals with concomitant chemo-irradiation for mouth, hypopharynx, oropharynx, and nasopharynx cancers.

The first stage trial enrolled 24 participants, who were randomised to receive either 500mg or 1000mg or 2000mg dose of EC-18 or placebo.

Around 81 subjects were part of stage two, where they were given either a twice-daily dose of 2,000mg EC-18 or a placebo for nearly seven weeks.

Data showed that EC-18 met the primary and secondary goals of efficacy and safety in the trial.

Subjects in the EC-18 arms had a decline in the duration of severe oral mucositis (SOM) through a short-term follow-up period versus the placebo group.

In addition, the oral immunomodulator reduced the occurrence of SOM through the conclusion of radiation treatment by 37.1% as against subjects on placebo.

The SOM occurrence through a short-term follow-up period dropped by 35.1% versus placebo.

In the trial, no serious adverse events (SAE) were observed between placebo and EC-18 arms.

Safety was similar across all groups, with the adverse events (AEs) linked to chemoradiation-associated toxicity.

Enzychem Lifesciences CEO and chairman Ki-Young Sohn said: “We are delighted to announce these positive results from our Phase II US study, which confirm that EC-18 is safe and well-tolerated.

“In addition, EC-18 may have a number of key advantages, including oral route of administration and convenience of use. We are excited to advance this novel candidate into a pivotal study and will also evaluate EC-18 for other radiation-induced inflammatory diseases.”

Based on the latest positive data from the Phase II trial, the company intends to seek breakthrough therapy designation for EC-18 from the US Food and Drug Administration (FDA) this year.

Furthermore, the oral treatment will be advanced to international Phase III trials.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy